ClinicalTrials.gov
public full text
Public Domain
PET Biomarkers in Treatment Resistant Depression
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor (MAOI) medication in this population.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Heart Rate Metrics as Potential Biomarkers for Predicting Transcranial Magnetic Stimulation Treatment Response in Treatment-Resistant Depression#231419
- The Effects of Sleep Deprivation on Antidepressant Response#968128
- Fluoxetine as a Quit Smoking AID for Depression Prone#1093401
- An Innovative Master Platform for Clinical Trials in Mood Disorders#1139831
- Stress and Inflammation in Late-Life Depression#1152546
Record · ID 1085529
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive